Apellis Pharmaceuticals APLS 深 沪
等待开盘 09-30 09:30:00 美东时间
23.005
+0.635
+2.84%
华盛通- 最 高23.01
- 今 开22.32
- 成交量 126.03万股
- 最 低 22.165
- 昨 收 22.37
- 总市值 28.99亿
- 52周最高 35.72
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 16.10
- 委 比 -78.26%
- 总股本 1.26亿
- 历史最高 94.75
- 量 比 0.99
- 振 幅 3.78%
- 历史最低 11.45
- 每 手 1
- 风险率 5.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know
During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
09-27 02:00
Goldman Sachs Downgrades Apellis Pharmaceuticals to Sell, Lowers Price Target to $18
Goldman Sachs analyst Salveen Richter downgrades Apellis Pharmaceuticals (NASDAQ: APLS) from Neutral to Sell and lowers the price target from $26 to $18.
09-27 00:51
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket
Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of TK-D2C AI Robots.
09-26 18:25
Wearable Injectors Market Worth US$18.91 Billion by 2030 With 10.8% CAGR | MarketsandMarkets
DELRAY BEACH, Fla., Sept. 9, 2025 /PRNewswire/ -- The global Wearable Injectors...
09-09 22:15
Anaptys Announces Participation in September Investor Conferences
AnaptysBio, a clinical-stage biotechnology company, announced that its executives will attend three investor conferences: the Cantor Global Healthcare Conference on Sept. 3, the Wells Fargo Healthcare Conference on Sept. 4, and the Stifel Virtual Immunology and Inflammation Forum on Sept. 16. Each event will feature fireside chats and one-on-one meetings. The company focuses on immunology therapeutics, with a lead program, rosnilimab, in Phase 2 ...
08-27 20:15
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
Apellis Pharmaceuticals, Inc. announced that its management will participate in webcast fireside chats at three investor conferences: the Wells Fargo Healthcare Conference on September 3, 2025, the Cantor Global Healthcare Conference on September 4, 2025, and the Baird Global Healthcare Conference on September 9, 2025. Live webcasts and replays will be available on the company’s website. The company, a leader in complement science, has developed ...
08-27 11:00
What to Expect from Kymera Therapeutics's Earnings
Kymera Therapeutics (NASDAQ:KYMR) is gearing up to announce its quarterly earni...
08-08 23:01
美股大行评级 | 花旗、小摩分别上调苹果目标价；瑞穗上调Robinhood目标价从99美元升至120美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从46美元升至52美元；BTIG：维持Strategy"买入"评级，目标价从620美元升至700美元
08-04 09:30
Raymond James Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $50
Raymond James analyst Ryan Deschner maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target from $52 to $50.
08-01 21:20
